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a b s t r a c t
The number of patients with chronically implanted cardiovascular implantable electronic devices (CIEDs)
keeps growing, and device clinics of major hospitals may soon be unable to fully accommodate the
increasing amount of follow-up activities. Consequently, the remote monitoring (RM) technology introduced
in Japan in 2010 has been rapidly gaining widespread application in the management of CIEDs.
A modern remote monitor not only acts as an alternative to a device clinic, but also as a security monitor
for the device and the patient. A number of papers have conﬁrmed the safety, feasibility, and cost-
effectiveness of RM systems. Importantly, remote monitors allow physicians to quickly detect and respond to
lead problems, atrial arrhythmias, heart failure, and other adverse events, which may also improve the
patients' survival rate. Several reports from Japan have demonstrated that RM systems are well accepted by
both the patients and physicians.
However, there remain limitations and problems of the RM technology to be solved, and rules and
guidelines for monitor management should be established to fully utilize the advantages of RM systems.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The number of implantations of cardiovascular implantable
electronic devices (CIEDs), including permanent pacemakers
(PPMs), implantable cardioverter deﬁbrillators (ICDs), and cardiac
resynchronization therapy (CRT) deﬁbrillators (CRT-D) is increas-
ing annually in Japan as well as in Western countries (Fig. 1). The
follow-up of the patients with CIEDs must be individualized in
accordance with the patient's clinical status and conducted by a
physician fully trained in device follow-up. Current guidelines
suggest 1 or 2 follow-up evaluations per year for stable patients
with PPMs and more than that for patients with deﬁbrillators [1].
As the number of patients with chronically implanted CIEDs
grows, the amount of follow-ups also increases, placing an
increasing burden on device clinics. Remote monitoring (RM) of
CIEDs is expected to provide a solution to this problem.
2. Systems for RM
Modern RM systems adopted in Japan are quite different from
the trans-telephonically monitoring system previously used in
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Western countries to monitor PPMs. The trans-telephonically
monitoring system is mostly aimed at ascertaining battery long-
evity, appropriate capture, and sensing. On the other hand, the
current RM technology makes it possible to transmit and store all
the data that the CIED is capable of collecting by using a commu-
nicator installed in the patient's house. In this regard, data
transmissions can be classiﬁed into 2 categories: remote follow-
up and remote alarm. Remote follow-up is a scheduled transmis-
sion in which routine CIED parameters similar to those obtained
during a hospital visit are transferred. Remote alarm stands for the
true real-time communication with the device, which automati-
cally transmits critical data related to its functionality or adverse
health events and patients' status. That is to say, current RM
systems not only act as alternatives to a device clinic, but also as
security monitors for the patient and the device itself.
In Japan, the methods of data transmission between the device
and the communicator, as well as between the communicator and
the Internet, vary among the device manufacturers. Moreover, the
transmission frequencies are also different. Table 1 summarizes
the characteristics of the 5 systems currently available in Japan:
Biotronik's Home Monitoring, Boston Scientiﬁc's LATITUDE, Med-
tronic's CareLink, St. Jude Medical's Merlin.net, and Sorin's SMART-
VIEW. Some of them transmit the data automatically as illustrated
in the upper panel of Fig. 2, whereas others require the interroga-
tion to be initiated by the patient by placing a special wand in the
vicinity of the CIED, as depicted in the lower panel of Fig. 2. The
third generation mobile phone network (3G network) has been
used to transmit the data to the data server. Wireless transmission
of the data between the device and the communicator is per-
formed using a radio frequency range assigned for medical
implant communications (402–405 MHz). From the safety stand-
point, automatic wireless data transmission from the CIED to the
communicator is ideal. Within the wired transmission design, a
patient can send the data manually only when he or she senses
abnormalities such as palpitation or shock. In this regard, the
largest advantage of RM is the possibility to transmit asympto-
matic events. The physician can receive such alert messages via
e-mail, fax, etc. Once the data have been transmitted to a data
server, the physician can also use the Internet to access this
information and, if needed, to arrange a hospital visit. However,
CIED programming cannot be performed remotely at present.
3. The expected role of RM in overcoming the problems
of CIED therapy
Lead dysfunction is a major concern in CIED therapy. Spencker
et al. [2] reported that the automatic RM surveillance system
enables physicians to detect severe lead problems early and to
react quickly. They studied 54 patients who had to undergo
resurgery because of malfunctions of the ICD leads. Eleven of
these patients had RM systems that interrogated their devices
every night. The rates of inappropriate shocks and symptomatic
pacemaker inhibition due to oversensing were compared with
those in 43 patients without the remote surveillance. RM systems
sent alert messages in 91% of all incidents, whereas changes in the
pacing impedance were notiﬁed only in 18%. Remarkably, 80% of
the patients were asymptomatic at the ﬁrst onset of oversensing.
Inappropriate shocks occurred in 27.3% of the patients in the RM
group compared to 46.5% in the non-RM group (P¼not signiﬁ-
cant). The mean time between the last ICD interrogation and the
event message was 54 days, or about 56 days before the next
scheduled visit. Thus, 56 days of reaction time were gained to
avoid adverse events. The authors concluded that RM may be
Fig. 1. The number of devices implanted in Japan has been gradually increasing in the recent years. Data were derived from the annual report by JADIA. CRT-P: cardiac
resynchronization therapy pacemaker; ICD: implantable cardioverter deﬁbrillator; CRT-D: cardiac resynchronization therapy deﬁbrillator.
Table 1
Summary of characteristics of the ﬁve remote monitoring systems currently available in Japan.
Devices Device-communicator
connection
Communicator-internet
connection
Frequency of
transmissions
Biotronik (Home Monitoring) ICD/PPM Wireless Automatic Transmission (MICS) 3G network (wireless) Daily and alert events
Boston Scientiﬁc (LATITUDE) ICD/PPM Wired Manual Transmission Analog phone line (wired) Patient-initiated
Medtronic (CareLink) ICD Wireless Automatic Transmission (MICS) 3G network (wireless) Scheduled day and alert events
PPM Wired Manual Transmission Analog phone line (wired) Patient-initiated
St. Jude Medical (Merlin.net) ICD/PPM Wireless Automatic Transmission (MICS) 3G network (wireless) Scheduled day and alert events
Sorin (SMARTVIEW) ICD Wireless Automatic Transmission (MICS) Analog phone line (wired) Scheduled day and alert events
ICD: implantable cardioverter deﬁbrillator, MICS: medical implant communications, PPM: permanent pacemaker, 3G network: third generation mobile phone network.
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useful for avoiding inappropriate shocks due to lead failure and
T-wave oversensing. Similar studies demonstrating the capability
of RM to promptly detect lead dysfunction were reported [2–5].
Patients with heart failure are at a high risk of mortality and
morbidity. Medical expenses associated with heart failure are
increasing, and approaches aimed at early heart failure detection
and reduction of the hospitalization rate are yet to be developed.
Patients with CIEDs also develop heart failure, and it has been
expected that utilization of RM will help effectively manage this
problem. One of the applications of the RM technology is monitor-
ing of weight and blood pressure. As shown in Fig. 3, the Boston
Scientiﬁc's LATITUDE device is capable of such monitoring on a
daily basis using a wireless weight scale and a manometer.
Intrathoracic impedance monitoring is also available in RM sys-
tems from several manufacturers. Yu et al. [6] showed that
intrathoracic impedance, measured between the right ventricular
lead and the CIED case, inversely correlates with pulmonary
capillary wedge pressure and net ﬂuid overload. Some other
studies also reported on the usefulness of this parameter [7–9].
In this regard, the CIED made by Medtronic supplies the OptiVol
index, which is calculated according to the accumulated difference
between the daily and reference impedance. CareLink, the corre-
sponding RM system, can send an alert when this index exceeds a
preset value. Although the OptiVol index has limitations in
sensitivity and speciﬁcity, it can be used as a parameter to detect
worsening of heart failure [10]. As an example, Fig. 4 shows a shift
in the OptiVol index of a patient with heart failure, which
correlates with the shift in the level of blood brain natriuretic
peptide and the patient's symptoms. The ﬁrst of the 3 OptiVol
index peaks was associated with an elevation of the brain
natriuretic peptide level and a symptom of dyspnea on effort.
Additional prescription of a diuretic prevented further worsening
of dyspnea on effort, and the OptiVol index decreased. As shown in
Fig. 5, St. Jude Medical's Merlin.net and Biotronik's Home
Monitoring also monitor intrathoracic impedance. Studies are
ongoing to ﬁnd a more informative index that, in combination
with intrathoracic impedance and other parameters, will allow
detecting heart failure with better sensitivity and speciﬁcity.
4. Acceptance and safety
A number of papers conﬁrmed the safety, feasibility, and cost-
effectiveness of the RM technology [11–14]. Lazarus reported that,
according to the AWARE trial [14], the broad application of a
monitoring system strongly supported its capability to improve
the care of cardiac device recipients, enhance their safety, and
optimize the allocation of health resources. Speciﬁcally, 3,003,763
transmissions from 11,624 recipients of PPMs, ICDs, and CRT-Ds
worldwide were analyzed. The vast majority (86%) of events were
disease-related. The mean interval between the last follow-up and
the occurrence of events notiﬁed by the RM system was 26 days,
which represents a putative temporal gain of 154 and 64 days in
patients usually followed at 6- and 3-month intervals, respectively.
The appropriate follow-up interval for patients with RM sys-
tems is an important parameter that directly affects the burden on
the device clinic. The REFORM trial described by Hindricks et al.
[15] studied 155 ICD recipients with MADIT II indications who
were randomly assigned either 3- or 12-month follow-up intervals
in the period between 3 and 27 months after implantation. The
authors compared the burden of scheduled and unscheduled ICD
follow-up visits, quality of life (using the SF-36), and clinical
outcomes. Compared with the 3-month follow-up interval, the
12-month interval resulted in only a minor increase in the number
of unscheduled follow-ups (0.64 vs. 0.27 per patient-year;
P¼0.03). Furthermore, no signiﬁcant differences were found in
mortality, hospitalization rate, and hospitalization length during
the 2-year observation period, although more patients were lost to
Automatic follow-up
Patient-initiated follow-up
Fig. 2. Illustration of types of data transmission by remote monitoring systems. Upper panel: automatic remote transmission. Lower panel: manual transmission using a
wand over the device.
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Boston Scientific’s LATITUDE
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Fig. 3. Trend graph of body weight, blood pressure, and other vital parameters displayed by the Boston Scientiﬁc's LATITUDE monitor.
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Medtronic’s OptiVol fluid index  
Fig. 4. Time plot of the OpitiVol index (black line) of a patient with heart failure shown along with the levels of blood brain natriuretic peptide (BNP, red dots) and the
patient's symptoms. Among the 3 peaks of the OptiVol index, the ﬁrst was associated with an elevation in the BNP level and the symptom of dyspnea on effort (DOE).
Additional prescription of a diuretic prevented further worsening of DOE, and the OptiVol index decreased.
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follow-up in the 12-month group (10 vs. 3; P¼0.04). The SF-36
scores favored the 12-month interval in the “social functioning”
and “mental health” domains. Thus, it appears that the extension
of the 3-month in-ofﬁce follow-up interval to 12 months under
automatic daily RM reduced the ICD follow-up burden during 27
months after implantation without compromising the patients'
safety.
The medical environment in Asian-Paciﬁc countries is widely
different from that in Western countries in terms of disease
prevalence, CIED implant rates, and other parameters. Moreover,
there are remarkable differences in the manner patients are
followed-up among the countries in the Asian-Paciﬁc region [16].
In particular, the role of RM may differ in Japan owing to its dense
population and developed transportation networks in most cities.
RM was tentatively introduced in Japan in 2008, and the reimbur-
sement system was launched in April 2010. Initially, there was a
concern that Japanese patients, who prefer face-to-face visits,
would not accept the RM system. Accordingly, a feasibility study
of CareLink Monitor by Ando et al. [17] enrolled a total of 203
patients who had previously undergone CIED implantation at
5 Japanese centers. A total of 470 transmissions were made.
Questionnaires were completed by patients and physicians to
evaluate acceptance, ease of use, and satisfaction with the system.
More than 87% of the patients felt that the monitor was easy to
use, and nearly all of the physicians were satisﬁed with the system.
The majority of the patients felt reassured by having their devices
remotely assessed and preferred less frequent hospital visits made
possible by the monitor. Thus, the CareLink RM device was well
accepted by both the patients and physicians in Japan. As men-
tioned before, currently all 5 manufacturers have developed their
own RM systems for ICDs and CRT-Ds, and most of them support
PPMs. The methods of data transmission vary, and the patients'
acceptance may differ depending on the system. However, it
seems that all systems have been favorably accepted by Japanese
patients.
RM has become a standard medical care for patients with CIEDs.
However, some limitations and problems are still waiting to be
solved. First, RM does not eliminate the necessity of in-hospital
follow-up. It would be nearly impossible to detect events other
than malfunctioning of the CIED system, arrhythmia, and heart
failure. As demonstrated by the Japanese HOME-ICD study [18], it is
also inevitable that false-negative events sometimes occur. Never-
theless, according to the results of the previous studies, the interval
between face-to-face visits for ICD/CRT-D patients can likely be
increased from 3–4 months to 6–12 months in Japan, which will
undoubtedly reduce the burden on patients and medical profes-
sionals [19]. However, as shown by the REFORM trial [15], stretch-
ing the interval to 12 months may increase the number of patients
who are lost to follow-up. Hence, an efﬁcient follow-up systemwill
be required to fully utilize the beneﬁts of RM.
Biotronik’s Home Monitoring
St. Jude Medical’s Merlin.net
CorVueTM Congestion Monitoring (showing recent 3 months)
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Fig. 5. Trend graph of intrathoracic impedance displayed by the St. Jude Medical's Merlin.net (upper panel) and Biotronik's Home Monitoring (lower panel) systems.
H. Okamura / Journal of Arrhythmia 30 (2014) 421–427 425
5. Emerging clinical evidence for RM
Many larger studies and randomized trials have been recently
reported. In particular, the ALTITUDE survival study by Saxon et al.
[20] is a large multicenter survey of patients implanted with ICD
and CRT devices across the United States. Within this study,
outcomes were compared between patients followed in device
clinic settings and those who regularly transmitted the data
remotely at an average rate of 4 times per month. One- and
5-year survival rates in 185,778 patients after ICD implantation
were 92% and 68%, respectively, whereas the corresponding rates
for CRT-D device recipients were 88% and 54%. Remarkably, 1- and
5-year survival rates were higher in the 69,556 ICD and CRT-D
patients receiving remote follow-up on the network than in the
11,622 patients who received device follow-up in device clinics
only (50% reduction; Po0.0001).
The TRUST trial reported by Varma et al. [21] was a prospective,
randomized, multicenter clinical trial comparing the safety and
usefulness of automatic daily RM in ICD recipients with standard
in-clinic follow-up. In total, 1339 patients were randomized at a
2:1 ratio to RM or conventional follow-up. Follow-up checks
occurred at 3, 6, 9, 12, and 15 months after implantation. At 6, 9,
and 12 months, only RM was used as the follow-up for patients
randomized to the RM group, but it was followed by ofﬁce visits if
necessary. RM reduced the total number of in-hospital device
evaluations by 45% without affecting morbidity. In the RM group,
85.8% of all 6-, 9-, and 12-month follow-ups were performed
remotely only. For all arrhythmic events, the median time to
evaluation was less than 2 days in the RM group compared with
36 days in the conventional group (Po0.001).
The CONNECT trial conducted by Crossley et al. [22] was also a
multicenter, prospective, randomized evaluation of wireless RM,
which included 1997 patients implanted with ICDs or CRT-Ds. They
were randomly assigned to the remote or in-ofﬁce groups and
followed up for 15 months. The median time from a clinical event to
the clinical decision per patient was reduced from 22 days in the in-
ofﬁce group to 4.6 days in the remote group (Po0.001). Moreover, the
health care utilization data revealed a decrease in the mean length of
stay per cardiovascular hospitalization from 4.0 days in the in-ofﬁce
group to 3.3 days in the remote group (P¼0.002).
The Home Guide Registry [23] and the ECOST trials [24] also
demonstrated the safety and usefulness of the automatic daily RM
technology. In the Home Guide Registry trial, the workﬂow for RM
was based on primary nursing, whereas in-person visits were
scheduled once a year. In total, 1650 patients implanted with
PPMs, ICDs, or CRT-Ds from 75 Italian sites were enrolled. During
the 20713 months follow-up, 2471 independently adjudicated
events were collected in 838 patients (51%), of which 2033 (82%)
were detected during RM sessions and 438 (18%) during in-person
visits. Sixty were classiﬁed as false positive, with generalized
estimating sensitivity and positive predictive value of 84.3% and
97.4%, respectively. Overall, 95% of asymptomatic and 73% of
actionable events were detected during RM sessions, and the
median reaction time was 3 days. The ECOST trial prospectively
examined the long-term safety and effectiveness of RM of ICDs. A
total of 433 patients were randomly assigned, at a 1:1 ratio, to RM
(active) or control groups. During the 24.2 months-long follow-up,
38.5% of patients in the active and 41.5% in the control group
experienced one or more major adverse event (MAE) (Po0.05 for
non-inferiority). The overall number of shocks delivered was
signiﬁcantly lower in the active (n¼193) than in the control
(n¼657) group (Po0.05), whereas the proportion of patients
who received inappropriate shocks was 52% lower in the active
(n¼11) than in the control (n¼22) group (Po0.05).
The majority of the existing reports on RM included patients
with ICDs, whereas the reports focusing on PPMs are limited.
The randomized, multicenter COMPAS trial was conducted in
France to evaluate the beneﬁts of automatic daily RM for patients
implanted with PPMs [25]. In total, 538 patients were randomly
assigned to RM follow-up (active group) vs. standard care (control
group). Over a follow-up period of 18.3 months, 17.3% of the
patients in the active and 19.1% in the control group experienced
at least one MAE (Po0.01 for non-inferiority). Hospitalizations for
atrial arrhythmias (6 vs. 18) and strokes (2 vs. 8) were fewer
(Po0.05), and the number of interim ambulatory visits was 56%
lower (Po0.001) in the active group. Changes in the pacemaker
program or drug regimens were made during 62% of visits in the
active vs. 29% in the control group (po0.001). The quality of life
remained unchanged in both groups.
So far, clinical evidence from Japan supporting the efﬁcacy of
the RM technology has been limited. The HOME-ICD study
reported by Watanabe et al. [18] evaluated the reliability of daily
wireless RM in forecasting the need for regular in-hospital follow-
ups (RFUs). Two-hundred ﬁfteen patients implanted with ICDs or
CRT-Ds were enrolled, and RFUs were performed at 3, 6, 9, and 12
months after implantation. Immediately before an RFU, the phy-
sician forecasted the need for RFU based on RM data (pre-RFU
assessment). A completed RFU session was classiﬁed as necessary
if an action was undertaken (post-RFU assessment). Overall, 663
pairs of pre- and post-RFU assessments were compared. The
number of pre-RFU assessments failing to predict the need for
RFU was 38 (5.7%), including 2 actions with high clinical relevance
(0.3%). Speciﬁcally, an additional prescription of warfarin for
subclavian vein thrombosis in one case and activation of rate-
adaptive pacing in another case were needed. Other actions were
of non-critical character, including reprogramming to extend
battery longevity, reprogramming to maintain safety margin for
pacing. On the other hand, RM correctly forecasted that 498
scheduled RFUs (75.1%) were in fact not necessary. The patient
acceptance of RM was also evaluated using a targeted question-
naire. Of 182 interviewed patients, 172 (94.5%) reported feelings of
security and comfort. The authors concluded that RM-based
forecasts appear to be sufﬁciently accurate to safely individualize
RFU, and that most patients have a positive attitude towards RM.
Many trials involving Japanese patients are currently ongoing, and
the results are very much awaited.
6. Reimbursement system
The current reimbursement regulations are in need of an
update [26,27]. In 2008, the Centers for Medicare and Medicaid
Services in the USA approved a revised set of codes developed in
collaboration with HRS, the American College of Cardiology, and
the American Medical Association that more accurately reﬂected
the services and associated work involved in in-ofﬁce and remote
monitoring of CIEDs. Speciﬁcally, the RM codes recognize the
critical role of the allied professional by assigning a separate code
to cover the work of remote data acquisition, receipt and proces-
sing of the transmission, technical review and support, as well as
distribution of the results. To prevent overutilization, the codes
may be used only once every 90 days [28]. Health systems in
Europe are signiﬁcantly different, which affects their approach to
reimbursement of RM and follow-up [29]. In the EHRA survey of
2010, 51 centers reported that reimbursement of remote follow-up
was established per episode in 8.9% of cases, but in 82.1% no
reimbursement structure was present [30]. A ﬂat fee per patient
per month or per year should be adopted for RM as part of
integrated care or disease management contracts.
Unfortunately, RM reimbursement is available only once every
4 months in Japan, and it requires face-to-face encounters. Mean-
while, especially in the case of automatic wireless RM systems,
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patients are monitored every day, and a substantial amount of
effort is required from medical professionals to check the data
transmitted by RM devices. The increasing number of the patients
followed by RM expands this burden dramatically. Appropriate
compensation would be indispensable for establishing a reason-
able CIEDs follow-up system at every hospital, so that RM becomes
a standard follow-up tool for all patients with CIEDs throughout
the country. On the other hand, rules and guidelines for manage-
ment of RM should be established. If reimbursement for RM
without face-to-face encounters and shorter reimbursement inter-
vals are approved, the rules for updating medical records even in
the absence of signiﬁcant events will be indispensable. Addition-
ally, rules covering regular communication with the patients to
inform them that RM is working properly may be required to
prevent neglecting the RM data. To ease the burden on medical
professionals, a new education system also needs to be established
to prepare specialists, including nurses, for managing RM systems.
In addition, the patients need to be informed of the purpose
and limitations of RM to avoid unnecessary complications. The RM
system was not designed to act as an emergency service, and at
present, RM data are not checked outside ofﬁce hours in most
hospitals. These data may include critical events such as failure to
deﬁbrillate ventricular ﬁbrillation, and the patient may survive
provided an immediate response is available to such an alert.
However, it is not realistic to manage an RM system in a manner
more suitable for a security ﬁrm. Therefore, before initiating RM
and follow-up, the patient and the family members may be
requested to provide written informed consent stating these
points.
7. Summary
The RM technology, which was introduced in Japan for the
management of CIEDs in 2010, has been spreading rapidly, and it
has become a standard medical care for patients with CIEDs.
Current RM devices are capable of not only acting as alternatives
to a device clinic, but also as security monitors for the device and
the patient. A number of papers have conﬁrmed the safety,
feasibility, and cost-effectiveness of RM, which allows physicians
to promptly detect and react to severe lead problems, atrial
arrhythmias, and other adverse events. RM also provides the
possibility to detect heart failure at an early stage and reduce
heart failure-associated hospitalization by monitoring patient's
weight or intrathoracic impedance in combination with other
parameters, which may improve the patients' survival rate as well.
Several studies have demonstrated that RM is well accepted by the
patients and physicians in Japan. However, some limitations and
problems of the RM technology remain to be addressed, and rules
and guidelines for RM management should be established to fully
utilize the potential of this technology.
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